Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study
16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks In weekly clusters compared to placebo during the weeks one to three two-month double-blind treatment time shows.
Weekly Cluster headache attacks
A statistically significantly higher percentage of patients treated with galcanezumab also achieved a reduction in weekly cluster headache attacks by at least 50 percent compared to placebo in Week 3, the criterion of Secondary valuation.
Security profile and compatibility
The safety and tolerability profile observed was consistent with previous studies investigating the drug for the prevention of migraine.
In the current study, 8 percent of patients treated with galcanezumab interrupted treatment during the study, compared to 21 percent of patients treated with placebo.
Four percent of patients treated with galcanezumab interrupted treatment during the study due to adverse events, compared to two percent of patients treated with placebo.
2% of patients treated with galcanezumab experienced interruptions due to lack of efficacy compared to 14% in the placebo group.
Chronic cluster headache
Lilly also conducted a separate Phase 3 study for chronic cluster headache patients, representing 10 to 15 percent of cluster headache cases. This study has not reached its primary endpoint.
To learn more please visit: https://arznei-news.de/galcanezumab2-clusterkopfschmerzen/